PODD - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

00:10 Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation Fourth Quarter and Full-Year 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. 00:37 I would now like to turn the conference over to your host, Deborah Gordon, Vice President, Investor Relations.

Deborah Gordon

Dalam. you, Thank XX:XX thank earnings joining call. and fourth for quarter XXXX you afternoon us for Insulet's Good President Officer. With and and Vice Chief today Executive Chief me are Officer; Wayde Shacey McMillan, Petrovic, President and Financial Executive is Bret Christensen, President of us Vice our portion for Q&A call. also Commercial the and today our with Chief Executive Officer of Both, the fourth and on results XXXX and call Investor quarter be the release available press replay the of our Relations section guidance this XXXX discussing website. will our I begin, statements during course be we XX:XX to certain of differ like may Before you that materially would made inform call current could by the expectations. forward-looking from Insulet and this to explanation for Please cautionary our in a the of SEC limitations detailed inherent filings statements. refer the statements such of measures financial with constant effect non-GAAP discuss respect EBITDA our of namely growth also will revenue, foreign We currency excluding performance, and is adjusted which revenue the to exchange. XX:XX These are and measures our our management and assessing what measures period. as from performance, we operating as to in measures of performance helpful period uses supplemental align interested parties with to believe investors, they operating other analysts stated, will otherwise year-over-year currency unless the a basis. of dollar with commentary rates, reported financial will a be Additionally, XX:XX on and percentage year-over-year growth revenue exception be basis regarding on which changes all constant call XX:XX With the that, I'll over Shacey. to turn

Shacey Petrovic

Deb. XX:XX everyone joining and Good afternoon, us. Thanks, thank you for

expanded and with another continued without our momentum to advancement with which markets, a strong operations. growth, manufacturing the U.S. embrace world. of X Omnipod of It people our is in strengthened its technology, be year, and it received and increased the the particularly we In our competition, end of FDA successful see could the and has year lives imperatives XXXX wasn't X mission of internationally was more both certainly our we Our international XX:XX AID of fourth to global X the around channel, pandemic, results through quarter access across recent the adoption diabetes of be. wonderful global Type ongoing strategic improve XXXX awareness diabetes community and strong mark pharmacy growing Omnipod XX:XX XXXX, unlock impact about. X, chain of into indicator execution continued clear While clearance believe Omnipod the the in will to That not challenges, shortages well of is including the excited markets. how a and we automated insulin it delivery Type global supply

to it launch markets. in delivery of our of billion plan. in a U.S. also growth marked XXXX, and our long-range to great We terrific and our critical automated a Omnipod are compatible serve consecutive are consistent start revenue results. XXXX to efforts XXXX FDA in we made with XX:XX offers system the of Omnipod annual now already we strategic commercial global year breaking marks in our XX-year our the in part It the clearance XXX,XXX X preferred The low tubeless sixth we commercial and factor model to Insulet the taken have revenue, advancing our goal this residing underserved company's effort in financial is ground remain making access. bring our utilization. X we'll incredible us we surpassed achievement. line provided smartphone with has form customers. in Omnipod reflected XX:XX In provide as the with progress team control greatest rollout and most and with and to our a in international our XX:XX The a unique innovation advantages strengthens customers today Insulet progress off the full markets We It XXXX that XX:XX reach customers more algorithm commitment XX% unmatched Omnipod. using These market and innovation milestone. first with with history. the distinctive an offers to insulin advanced X, or Taking value market approximately $X Pod. back, and pay-as-you-go has patient and critically epidemic the and technology diabetes competitive provide complex growing pump on is brought a should through business benefits global the pharmacy by U.S. deliver step life-changing we

people an diabetes increasing CGM and awareness with at adopting wearable rate technology are However, as use accelerates.

our capture a Omnipod of relentless broad our XX:XX leader new awareness based trends over and simplicity Type adoption. continues approach well our continued the differentiated to access of access our the delivering in for a the long-term, on in Insulet X technology, through outcomes we our customers are daily demonstrated customer continue pharmacy. form great given over X and improve significant opportunities the factor, as of experience. to from U.S. These with multiple and injection XX% to innovation to customer-centric as offer focus XX% Omnipod market our efforts between XX% Omnipod Our along represent new In to and benefits, driving the affordable remain the U.S., Type on growth of customers we

growing now costs model our to access Omnipod strategy. Omnipod available to are Omnipod to for pharmacy U.S. and our strategic majority include global market our provide which drive expanding awareness, four-year with people awareness easier is users an delivering market continue The grow period. than penetration, to provides operational Payers our pharmacy XX:XX expect the Today and burdened of channel. and and global market not innovation, is XX:XX expand focused addressable addressable share. lock-in our excellence. more We our Omnipod customers. I pay-as-you-go imperatives, driving through update essential consumer and in total of our and access the will on Expanding ever lower for access

or Omnipod nearby can up can pharmacy. X and like from fees conveniently adopted technologies picked upgrade be New be supplies without upfront a

why for for access less pharmacy, model, U.S. majority For experience globally. the the DASH, pharmacy. our and successfully Omnipod years The Omnipod to and the started through on the are is The business is than of Omnipod user and U.S., this The new XXXX the almost with pay paying consumers the expand payer, in in the our broad exactly vast month affordability. great this and have product and pharmacy access Almost customers nothing. DASH we've DASH, all the risk of to is covered enhanced the each $XX access we secured far is and average in for lives easier access been less over last pay-as-you-go of driver to this primarily XX% has means customers it we in through growth primary Omnipod we investing here. means XX:XX many affordability. XX:XX of our assumed innovation Essential two now our secured

to of Omnipod the is with on life. par improved cost users While and DASH quality Omnipod multiple daily of injections, outcomes provides

for through We for to adoption. logistical campaigns Our can reduce and cost direct-to-consumer our afford is administrative continue the Omnipod. customers, ways look also all raise XX:XX they so to and to helping drive efforts advertising awareness hurdles access and to

continue efforts select DASH we drive Omnipod Our positive of international programs across planned customer contribute X. U.S. to Omnipod In a our and the our to response XXXX, markets to DTC are and now ramping expand increased growth. to drive and awareness and

will date, Delivering the experience fully Omnipod the we launched. to excited success have at X once are heart is XX:XX the DTC what to our Given customer best campaign we is our do. see of impact

being set. smartphone is true phone form the alarm, and system, and like Omnipod algorithm the of our on unusually novel market. based XX In Pod first or pages is others addition years, is With includes the body No to delivery. the diabetes X AID is have it possible full the complex XX:XX three Full adjust of sophistication, dismiss next first thousands diabetes Omnipod entire experience reviewers a controlled smart control is controlled no pump the an our our phone fully we've Omnipod. control, AID it world's history working controller phone and system, the only agency calculator. of tubeless using there next The on. at settings pod simplify no point unique control It wearable no we been category we to This regulatory including phone out the improving level infusion been of all and factor factor innovation confident is X other For far management our traditional AIG system as leapfrog beyond tubes of on and and insulin an the Full redefined management. experience and XXX(NYSE:K)s, bolus are innovation phone. pump customizable on lead on an the We've what on form pulling a build required separate that simplicity set and with to market to takes XX:XX pump. will is in three data. level. prime submission, of change is there level

Our and limited access best market customers already system, and XX:XX experience of is designed ours upon market over releases begun with release and the test new support are possible to release. customer has the practiced major are and customer innovations full market Limited moon. best launches our early training ensure build the

teams have simple customer we platform. product through manage their to paperwork We benefits enable and In Customers now pipelines verify process efficiently to modernized a our can our transformed the seconds, pathway complex pharmacy access and pharmacy. service access XXX% to also addition facilitate field a products. users how request, digital XX:XX innovation, can Omnipod on-boarding more in streamline a enjoy

we expand During and the by study limited will We expanded XX:XX many rollout within year can't excited to We coverage at also coverage for progresses. for Omnipod system X this this Omnipod ensuring tremendous FDA Omnipod team and community XXXX. contracted two. improved Omnipod know nine our for after recently FDA experience clinical as clearance available from We an Type age down important clearance, X the design as take our Type conference to in we plan results to caregivers expand the our can continue vulnerable provide our April. our X diabetes. XX:XX established and broadly the for and XX:XX completed clearance. to benefits everyone. innovation months to and And indication the are waited we swiftly the the the policy. X outcomes diabetes delivered with to able X to now ATTV This their is to to study most we to further XXXX, population more three submission feasibility the in for coverage diabetes and to our laser-focused on everyone be anticipated expect deliver teams move X's prior forward system Omnipod enjoyed the is study in wait our to Shortly to strong is as to to market X simplicity is study participants. look indication release payors access sharing to pivotal learnings intent We are more

pioneer continued We the U.S. X. have space in X pharmacy given adoption proven now our strong the Omnipod Type and and be DASH, expect benefits a access of Omnipod channel to

as strategically is to a X we continue DexCom's integration invest is our and platform Libre. development pipeline. Omnipod years. that X, as work GX with FreeStyle Our product you'll in Omnipod progress Abbott's us coming we both in the a app Even making advance terrific is launch robust XX:XX iOS see

are areas. Omnipod in Beyond three X, we focused

working on addressable market. grow our are that We will advancements

Over controller platform experience we by we the for all next-generation aggregating years, data, and digital management developing enriched level Omnipod and digital products enhance can are We diabetes technology, user to innovations easier SIM XX:XX make stakeholders. further X creating on and cards and and data built our for last have our several are With the in podders. every analyzing better AID capabilities. customer we

deliver geographic come. filed decades can Turkey. and diabetes future of serve more foundation as to XX:XX expansion. our built expansion existing This With create will We rollout Asia DASH strengthened for across targeted into In our physicians Omnipod digital strengthen our industry than These Pacific build through year. portfolio. our secure the develop through more upon and actionable efforts our This provide sharp differentiated innovative positioned to we as strong new our driver the people the offering. entry innovation a markets to access and burden our growth. advanced our will insight improve these well with international Australia These new providing investments, future brand mission also users broadened have technologies to any and we previous XXXX, help to ensure another patent growing outcomes, we past and and XX:XX the health entered both expanded We in for are for Omnipod lessen we applications as year, XXXX product property by efforts and leading and and preferred patent Omnipod user on capabilities. region into focus we intellectual on on innovations

additional XXXX international our Our X in expect We markets XX:XX to Middle in expansion East. to underway. market the Omnipod deliver efforts are

and accelerating, to X focused international people product X our near increasing We in benefit would over we presenting on bringing of pathways XX:XX and progress being are for around bode great once choice the We technologies we the world globally. in and Many these to for is it time. CE from Omnipod are that I'm of we share reimbursement launch happy headwind, them look forward Omnipod making markets. additional Omnipod marking awareness adoption term and Europe. market AID it submitted acceptance, while to well

building business well creating XX:XX in operations including Omnipod also to strategic are the a our year millions times. of markets driver our the to and pipeline. chain efforts. unprecedented can in more underserved operations our a is for our in XX:XX impact for critical additional new and of demand advancing continues Pods and global Omnipod mitigating and capabilities on execute secure full our strengthen we Diabetes resilient challenging The will Insulet. teams development priority chain the continued customers. steps growth commercial access during a X. as great We reimbursement supply positioned global progress our critical XXXX, manufacturing support world our are well efforts on release environment. to the regulatory remarkably and entering everywhere established strong these uninterrupted international build team produce and extremely manufacturing growing Investing We DASH These innovation global market We component upon we of scale. made despite and Our to remains long-term XXs successfully expect supply and a represents our

finished Our years capacity. growth and the excited we XXXX. ahead by strong and XX:XX will year another in be plans XXXX constrained closing, extremely not are about In

X expect year Omnipod We launch the to U.S. in this fully

to have roadmap. markets Omnipod an We innovation we our X and advancing are strategy our to and exciting international bring robust

Our talented commitment and success our our to unwavering mission. to is due team their

great the one while year, U.S. and We over the lives of company positive satisfaction, Workplaces they directly an the listed and have in an our financial work Insulet to employee named were of amazing our place as These one and feedback both XX:XX our XX:XX strength. Wayde. recognized part to and another of reminders managed to as of the past customer now built are call we and of power recognitions companies engagement, with social on in come the customer improve innovation, being award culture. I'll separately responsibility winning diabetes. This and the people on from XXXX because for Best based a turn also one our impact employee past communities wonderful UK, Institute mission top This of people the Women. December, Druker's on in

Wayde McMillan

you, Thank XX:XX Shacey.

on year Our for quarter progress performance fronts. of fourth closed many another out Insulet

a revenue QX, drove range focused was the range. revenue, DASH growth. Also customer fourth our and new volume XX almost channel investments a our strong pharmacy over quarter, We fourth foreign generated volume. of over also we execution imperatives revenue strengthen adoption. profile XX:XX basis was global new growth pharmacy XX% starts. The U.S. U.S. U.S. trend XX:XX for while Our U.S. our On driving our headwind our volume our International all Omnipod year. record of customer strategic XX% increased of reason above currency value through success with continued guidance In the due of Omnipod In reported meaningful our channel point guidance starts for to total Omnipod Omnipod U.S. a U.S. growth prior which contributing stakeholders. starts below our DASH customer revenue continued to guidance consistent basis our XX% new our we range. primary exceeding delivered total the X%, finishing through for continue record XX% of grew growth and the Omnipod and revenue to driving quarter, of financial was

was European into to points. by reduction $X of Our balanced estimated negatively XX:XX by XXX returning sooner It our approximately impacted channel This growth basis and more was normalized an growth guidance. due inventory not factored rate from million much distributor the anticipated higher to throughout impacted a levels pandemic. our QX it the than carried fully occurred

revenue fluctuations in reminder, results. a and can distributors regions, sold impact international of the in levels through our As majority our is inventory

to impact year. foreign model. on our basis increasing by currency AID of We international annuity a point was over for Omnipod, On the XX:XX a headwind affected compounding continue the basis be competition also XXX and prior reported pandemic

XXXX estimated This higher growing line are pressure a achieved in growth. year XX:XX as with model. by during XXX expansion. in XX: stable record to partner. advance few long-term margin demonstrating fuel XX.X%, production I from of at XXX% favorable benefiting and XXX by as margin international of the reported constant mix channel fourth investments of points for Operating to we offset drivers guidance will expand our associated result These increase XX:XX revenue growing pharmacy quarter total was to our also that manufacturing invest position the were grow XXXX. volume a our manufacturing XX.X% offset in our under our fourth in was The This we mission. inflationary strengthen was lower drivers higher costs driven the operations. will XX.X%. is pharmacy from basis. were overall entered full line We in expected due growth as on higher sell basis a the global invest while XXXX, with manufacturing. the up benefit during a in up to year growth These adjusted were to cash revenue manufacturing we financial our These come. remained and year product across strength strategic product points includes XX:XX XX our the further Our our higher-than-expected in finishing XXX growing in basis primary quarter, areas our pandemic. basis were increased available credit mix was sales utilization over one-time expenses drive marketing XX:XX inventory year our with capital. designed we balance we adjusted with $XX are costs improved total U.S. global our up XX:XX and durability representing up U.S. million drivers points. innovation through expectations from the with the our benefit basis margin XXX and revolving steps XX.X% mix currency Our mix innovation volume currency demand Operating the In ramp range channel, margin foreign of of to revenue points by business was of through global XXXX, business cost scale attrition years of in costs and delivered prior U.S. and in and an significant touch with for gross as full and margin out to achieving delivery continue QX. On with partially point XX% year-end points. on We costs were this of past had our expectations. XX.X% expected inventory. increased pipeline, we our basis facility. revenue volume minutes. our ended and and showed margin partially EBITDA line Turning a component total ramp XXXX basis above and investing Pod we growth Drug a operations our in roadmap Both we XXX series to or efficiencies further and step Turning $XXX to increase more our and Gross and as we a manufacturing. sustainable affect in strategically continue annuity XXXX basis, EBITDA profitably, and Omnipod expectations year as of capabilities, that also of expected another U.S. our and were addressable market year, long-term total while X.X an gross a over and and will Both was expectations. company results, the we XX% billion growth consistent by million reduce to in liquidity, cash prior and capital structure we critical XX.X%, margin our a took further XXX strong of Operating from

our growth current are intellectual and acquisition to positioned supply further mitigating strengthen capabilities excellence key the suppliers, We efficiency well our while we allowing integration to competitive quarter, our finalized the strategy. XX:XX which production brings More operational drive property risks. finance of and recently us in-house, of and chain moat, one expertise in strategic vertical

have We global to steps manufacturing taken capabilities. strengthen also our additional

China region We by location. have one in operations consolidating production into in optimized that

product the year, and turning to over of we our manufacturing growth in by increase and efficiency expect to time. for our goal revenue growth further to XX% diversify XX%. consistent new Omnipod to XX% revenue Now also expect invest XX% of U.S. a total line, XXXX drive for We XX% globally XX:XX full growth plan XX%, outlook revenue international gross with margins to location to Omnipod we to company of total higher

unique model pharmacy our driven Omnipod growth Type volume growth X pay-as-you-go and Type markets access. by Our channel will X within and DASH be primarily and

momentum release so and begin of XX:XX to X, to half benefit will begin growth term. long of to more half we the and latest even Omnipod benefits in we from commercial investments. gain higher X We the past commercial and the the Omnipod as of also versus move this the other year headwinds year pandemic expect to this first launch realize from contribute anticipate We of over second will growth the be innovation the

reminder, a will release market X As adoption a before its for of ramp transitioning we model annuity our For full we Omnipod, revenue offset growth the in expect the adoption, AID related full and are year and the impact pandemic of limited Omnipod ongoing partially international launch of driven time to XXXX the XX:XX time to period due of range market given release. by take by X% and in nature competition XX%, DASH to of headwinds.

We with we expect first expect related improving strategic driver to our to half growth expand X resulting markets. conditions the year COVID. international the slightly to and a investing as long-term remain focus easier to to a a as global international to growth bring the and of higher XX:XX expected our will footprint continue international We be comparison, versus from in revenue well second half also Omnipod

gross Turning For as margin of half expect XX% XX:XX it first year to full during levels second to for gross the margin the elevated XX% were XX% of drug the XXXX, to pandemic. delivery, and half. be revenue year we as to achieve expect to higher we compared in to to the decline expect XX%

global in inflation. costs decline X and Omnipod and volume, capabilities manufacturing U.S. driven offset mix, partially pharmacy this product by associated our We operations with including strengthened ramp We to U.S. channel. our and manufacturing the prior is year costs manufacturing higher expect associated by volume with be the benefits and increasing expect component ramping the XX:XX of higher from

rise marketing expect to our direct-to-consumer scale investments we in financial revenue continue a term commercial-related invest expect operating further it. and innovation This fully we we activities. XXXX, margin we gross begin our expand pipelines, margin as we are mid-term We and other as profitability. robust as manufacturing Looking still our goal the slightly long to to includes toward expenses over XX% see business key and see and further below of driving to clinical scaling our gross XX:XX our near-to in progressing benefit full beyond while XXXX, of During the growth areas efficiencies. increased

market Omnipod as experiencing operating XXXX pivotal We a pressure be rapidly we will are X inflationary strengthen in expanding also year under-penetrated. remains position within and launch a our and large expenses. that

our innovation we per This of Omnipod we operating approximately invest each year, short At which we basis as new iOS and X most mid-term XXX the drivers. growth of growth goal our over our majority strategic XX:XX Libre long-term internationally, We invest accounting in with guidance associated insignificant that million an approximately non-cash amount, to and inflation, the with integration points to at and our year year. reduces effort expense team most unchanged heavily of notes as in SG&A. is continue increased with convertible expansion development much investments XX the continue interest start interest our more. to XXXX, expense cash remains Omnipod adopted expense XX:XX and expect GX advances we make launch, the pressure our of to from target be margin the operating will within Even of X

XXXX XXXX investment expect grow business. quarter our first in throughout to we revenue our Turning XX:XX XXXX slightly expenditures now Finally, will continued from capital with guidance.

company growth XX% total and expect growth We XX%. to total of both Omnipod

Omnipod, XX% XX%. we growth For of to U.S. expect

international QX in from and impact DASH continued due competition X% be pharmacy drivers new XX% will customer recurring of new core Omnipod the the driven DASH the model the consistent following starts by customer revenue XXXX, expect compounding channel. record Omnipod partially through offset lower volume Omnipod setting additional by expect to largely an our We of XX:XX benefits XXXX to the in growth pandemic. We U.S. AID adoption, starts

launched, growth to our progressing. QX growth are year solid each X XX:XX drug our year Omnipod XX% is to FDA, QX of under markets to of progress. than be the higher XX%. in another strategic initiatives timing. active and In production expected delivery we conclusion, of to we expect Finally, we The expanded revenue advancing quarters our is preschool to due the completed Omnipod U.S. international X Type filing at are is bring the indication review X the and efforts subsequent

growth for will year the our to strategy expect to competitive years XX:XX XXXX be we advantages position sustainable to advance for call existing and to build over With as questions. our we the call that, come. to Dalam a open turn for We upon transformative Insulet

Operator

Thank Bedford go from the XX:XX you. [Operator James. comes ahead. first from Our Raymond Please line question of Instructions] Jayson

Jayson Bedford

more afternoon still build quarter the in down, Good wanted inventory I on Hi. it international in be (ph) will unwind XQ same within a there and international is got and just the last then still quarter-on-quarter, start XX:XX congrats markets, and add related increase net quarters side. it changes the $X basis that the pricing approval. kind internet to XQ install got question. to is guess inventory been just on fourth fourth the the base the I to -- is over international of to on function of specifically in terms I the and the so if just way back the a If has million quarter down few the and

Wayde McMillan

the think Jason. something U.S. this And been business, more XXXX. be for impact, quarter certainly we've them, are in in because experiencing hit channel inventory balances We taking And the seen the to with down, had monitoring momentum Hi, throughout business we the Sure. it it's did. pandemic. with conversations we Thanks at actually but out, tailwinds we had didn't in a they carrying the distributor end it they’re higher going we the and throughout question. XX:XX you of international call were as unexpectedly

XX%. growth up normalize for it So takes including you about our if to rate, as guidance, we you didn't that said,

the and just with will really XX% through there nothing business consistent the that our distributors out call our regular and so XX:XX between growth year, a it flow of had the quarters. distributors. so normal is ebb is pretty to than we've XX% to throughout with Most and patterns order other internationally So

international said we've CGM So growing to consistent. Shacey And to on and the in quarters that's growth got new can't customer growth to as year over in get a remarks, countries, pretty XX% and And And approval of for our persisted the quarter-by-quarter target between X you off. the growth. highlighted the competition up overall, reasons. starts, we've that called has we and over last are XX%, our our ended the starting the AID the for year segment couple out then AID that in Omnipod impact has well so in AID. take prepared as longer wait four as with Obviously, pandemic markets as low as participate off systems certain that main of know, high-teens been we XX% we've an market

on we of So think back We're targeted still still growing. low-teens more innovation high-teens XX:XX that's to sustain It's to XXs low there, get we our run where with that and we to the can down X bring growth, can't double-digits wait that growth Omnipod of and the range mid-to growth. international is base type business. business into strong

Operator

next Thank XX:XX go Josh Please Cowen. comes you. from ahead. of Jennings I show our question the line from

Unidentified Participant

could year? Omnipod And With that we is for follow-up similar today of in Mark you. should that a Is this CE for CE an in three expect months, timeline timelines the X. the EU now, hands. have Eric you Could U.S. half milestones help Mark five you've approval second Josh. to on submitted will us launch to to that Thank of receive This said there? decision an then ask be I'll XX:XX limited safe assume once any delivered be your or you announcement to that approval you the the for understand it in OX

Shacey Petrovic

submission. a that the of for some and know pathway confident take submission, great obviously this could very be Thanks, have Device Regulation for time and regulatory it new question. review the Mark. that we're CE data Eric excited under know, Medical timeline a a quality as you the may active us secure We this Yes, to beyond but the We are XX:XX don't share complex to Great. to is approval. for pathway, in really we looks

we guidance given for haven't So, timing.

select that we the where for release to markets a handful terms that international from part we let we that our Thanks then limited to limited release know then there. we into wanted strategy, and In Just expanded under it's the XX:XX are we getting and like, the market. of will likely as looking of how still look in similar question. part there, limited with what market expand rolled of started markets market as from out markets and are DASH market everybody release onto the the out of active to that review would finalizing enter forward very very

Operator

Thank XX:XX you.

Our next go from the of question Morgan. Please line from JP comes ahead. Robbie Marcus

Robbie Marcus

taking questions. the Thanks Great. for XX:XX

wondering for starts. limited little year new quarter was if I U.S. a looking it's patterns elaborate thinking patient first say quarter, and was just full you and the having Street could as the for on impact buying well. launch the fourth the good a the So user and below on is U.S. I had where but would

get of are seeing if So you're buying sense just love patterns would waiting. in a to patients those and what

Shacey Petrovic

I'll guidance it's planned. and Maybe as QX. the Robbie. can Wayde to release the into and then factored progressing market speak limited just few what's been Sure, weeks is a exactly XX:XX start for But

I had in our looking are of the terrific is has all from are while said, pathways been it insights those what sort product early we're continues and looking as for build to that think we experience, we're feedback getting training we testing onboarding participating our team access. for the

that doesn't is so I it and strong it wouldn't in far was the of there look the -- the it there Omnipod was. performance early get it to that. X given people days, are but would which certainly that the for as Omnipod U.S., we expectations Omnipod, buying strong good, quarter so waiting And relates fourth but very patterns, for you the And our sure just indicate indicate X are are to quarter think would out ahead how waiting quarter and in although so, at encouraged. I'm people onto fourth are

Wayde McMillan

QX. pharmacy a behavior year have the that then, what is, strong And up couple buying QX our year the we'll QX behavior particularly ago, with given expectation mind moved Robbie, see trends result those thing people to that behavior volume what's wane and a may the just move we XX:XX not, regarding QX of And volume strength years somewhat that in to U.S. thought in -- when compare built and we've we of guidance is similar we Great. in into up if buying the wane of guidance, keep seasonality, XX:XX the one just people following higher pretty pharmacy last built-in our as QX the So QX. driving year this there 'XX the in XXXX that in into start that channel, in inherent more and we and into in but and is stocking channel. good pretty learned what and our from see but of and or in similar in experienced though to seasonality strong behaviors lower we even percentage QX, pods fact are with last we'll marketplace does still in we're utilization wait over half into

Operator

of XX:XX Fargo. I next from Wells Thank comes show our ahead. Lawrence go line you. the Please from question Biegelsen

Lawrence Biegelsen

Hi. you launch to XX:XX did to Good I the would be nine or months five taking the thanks three and Shacey, for question. afternoon three hear limited say months.

Shacey Petrovic

Three XX:XX nine. to

haven't saying That's that. our all We changed what on we've estimate been along.

Lawrence Biegelsen

Thanks low question. and of And end you my is versus the kind you the of that start the is will, would question taking range nine to what get the lives, covered high you XX:XX so such exiting a what wide to of if my the gets for end that, months for XXXX. goal of what why you kind

Shacey Petrovic

XX:XX Yeah. Thanks, Larry.

on the to our dependent across full is moving getting release really different just journeys. use So of through of market customer days number

MDI coming or people coming and who CGM So are Omnipod traditional getting tube users pump CGM users we onboard, from have people naive. getting onboard, from

and pathways each on-boarding So the training experience. want confirm of product confirm pathways, of the to we look and to the those course, want across we

doing So working we're that then build we six XX:XX And we if may things also to push goes months. closer some that, nine be us flawlessly, that to at If we'll address, learned of three that in want then that or access. all to months. we're while

we've make then we've experience, market got got And full will governing the want release. access that's which be want want access got there factor We possible and best there's it, experience be and just into the in we expect really demand to we move best don't we where so where once enthusiastic position. to customer out a when to we know it, possible we've customer going sure

at everybody assume we And that experience would and that months to so recruit I is that flawless that we guess assume pace months things nine to we address. that want three the learning some and really want we're would the

Bret Christensen

important full I'll why XX:XX of is, Larry. want Yeah, Bret. it's release. add at the just to we market reasons the quickly one that Its move

the ordering user our for period a Remember, process, testing of onboarding access head launched lock-in and factor go self-service systems we we were before our had so amount on tremendous And were four-year the we -- the have why testing tremendous the starts XX:XX the of parts some what which amount to process, of that we system to LMR flawlessly both from FMR. we're product. said well or during them X. along as We to full move that with as can a don't we self-serve, market to a systems ahead with continue that the be demand base provide where probably to is be self-start need and those so reason limiting existing to not And to access going want to product podders Omnipod there's really Shacey it’s because on to so puts get able the and so to the a release, of move those move during with we focus new we the start, quickly of going is so we're you DASH and two but at be of were ahead mentioned, users.

to really quickly will those that and the ordering with we access process be on-boarding So once us enable will systems, And move FMR. level. probably get an during acceptable comfortable two

Operator

Margaret Please Kaczor the question next from I you. comes Thank of line go from XX:XX Blair. our ahead. William show

Unidentified Participant

moving exciting XX:XX and of going a for Margaret. the guidance. question. for on on There is things lot the on Hi. pieces. This I lot through Thanks to Brandon is good wanted taking of the XXXX year. focus A

not global about maybe could as I And and X of was investments, are percent in launch up. ramping what Type that you cadence a of guess factored just what on is maybe the considering is or three if those of Omnipod that What for of guidance. you what X. I talk are wondering, mix factored So into a into DTC say And one focus then a guidance are let's factored of things global kind I what's would for is the users.

dynamics color and what be helpful. around any factored the those what in and is guidance So, would is not

Wayde McMillan

start jump Sure, I XX:XX drivers in mentioned. that would and of to one, can I'm Its Wayde, that you the Bret then couple business a Brandon. like sure, Hi. on

to achieved we very International, strong So end our much us fact our and product record in they high the be in of for setting guidance again. lines will across similar XX%, the had growth guide the XX% XXXX at revenue end, high XXXX we U.S. base guide U.S. to all basis for of the in high-end off higher

where And have and need last What lower so we so at or just the even Bret keep base annuity the get in though the the including range. significant the months it our end really in existing we percentages size have takes on than end three our at the are the nine specific the things months. given we're talked of we channel about in nine to dollar full U.S. from difference year-to-year what or months, is rates are if pharmacy and we slightly pay-as-you-go it and is sell-through year low that an XX:XX are release eye as market given of are whether model model, the we at the And of year, three with whether watch that scenarios guidance, it to obviously and Omnipod X. running a the launch Shacey us the months pretty the on to the growth to

few dependent. monitoring new so XXXX customer X to it to will Omnipod been closely quarters and XX% is interesting, throughout consistent Type something XX% and that's We've very be. been we the The the at be starts so X expect again of that's of what be last X Type it year. we'll our pretty And mix would throughout over have

Omnipod in as our as X Type X. has said However Shacey remarks on we're X Omnipod prepared Type X ramps working and indication

we for X in So really X we still X have lower had indicated our could XX:XX is mix increasing time. driver an good it's ramps, where be And products. standpoint, lack maybe a Omnipod awareness of the type that DTC only DTC do why from stands point the given that Type driving then as think this a for for today you strong on us. success market Bret could think talk to awareness we in at and

Bret Christensen

XX:XX Yeah. Thanks, Wayde.

headwind U.S., X once what to system complete I the an lack most but really pointed we will Omnipod AID for we think get the We have of not a So to the being is just offering. us, in DTC internationally, my pharmacy we but the we've marketplace for the mind, factor form tailwinds when Omnipod frontier next the us. and in X to awareness Type and these add becomes had best in of AID now

So that in the I a conversion we've XX:XX even forward at DTC be addition already tremendous. messaging improved starts come and in new should message to to better an Omnipod. been made AID tremendous enhancement leads to in drive those to learnings rates. converting strides have in should the better That look And TV our commercials, of DTC,

full throughout release doing forward message that do. message to see Omnipod So the it’s look something we'll in include year. market continue those our evolve to approach to we as X AID you'll We And of it commercials. the TV

Shacey Petrovic

into our have active just Omnipod are XX:XX are factored under Brandan review, we X And note, preschool one them to the really both although excited and international not expansion guidance.

Operator

show Baird. I our comes go Johnson next line Please the question of XX:XX Jeff from Thank ahead. you. from

Jeff Johnson

just more in markets. of Good took maybe afternoon, you ask, of, question. guess not international me I Omnipod But was question on international X whether kind kind guys. there Shacey detailed last let a or my Hey. XX:XX

that window tough let's Germany is but all get UK revenue? to some is or of reimbursed -- about. to months and it it something know there window your if didn't is let's I another XX predict. say window OX XX-month like rails do you the to we think once pathway to so conservative that for reimbursement MDR six something that, countries more Thanks. happen, that or long or one, largest at could of to X on it's put any window to July CE about, What's think like whether kind So a get your six-month contributing have just think to Do we that that, guide would France importantly, that's were anyway number meaningfully that think how international in I actually to get take on more start Mark

Shacey Petrovic

market terms XX:XX of is a work Yeah, it's and such development business work is Europe The thing, lot because know, question all we market is for have international of pathways. as XX reimbursement a about good and Europe different models, XX different one we good if news us, underway. talk different different It's or Jeff. in that plus we countries, but registrations there

but today, the So will in doing faster depending we access are terms on who for and some market, have the some X. be go go slower of establishing there development teams will will work, and work coverage Omnipod market

So I can't really put on MDR. a window

for submission. still in -- the And we and not We are are reasons this under into pathway review, point. MDR, one this of the so year. that is -- one an it's not early it's We're built confident just guidance established. It's just it's pathway it's days why unpredictable at of the very but

once work market that make to looks have we as obviously CE need know on And a I we to that similar access you of market that progress -- U.S., terms would Mark. registrations, market limited let et will there. market what based We release will we the we do release development say XX:XX have looks in the just into in remaining fairly establishing and cetera, move

Operator

from you. Citi. Joanne from Wuensch our I the XX:XX show line ahead. of next Thank question go comes Please

Joanne Wuensch

taking evening XX:XX for you thank Good and question. the

do to pathway? going submitted buy two-part regulatory but How want X that it and do a with that integrate them ask to think long be and about what's it You to by you a takes you I the lot Omnipod question. certainly X needs something have Libre it's GX. And is on, or

Shacey Petrovic

a Type lot very Great. exciting. going now iOS, so and there launch, XX:XX is yeah, pipeline, Joanne, exciting preschoolers course, CGM on it's talked of integrations, about we've a and international and very X today the

work with some Libre is GX quite well. been for I integrate underway think has everything to and progressing time. with The

And so that Based the interoperable there. ICGM pathway. a good not is of making pathway actually be and progress about GX regulatory submission. things for beautiful on should one there That's clearance and DexCom the

go there that work. long be to We to really And do responsibility the and well. and should now, is work to the own our require relatively submissions work get pole is partners to tent support those need that and XX:XX regulatory with likely may ours a so submission, underway our the Libre and so it's require And development in technical as technical straightforward the then submission, those that manage. work would clinical we right the

Operator

you. Thank go from Danielle ahead. next from comes our I show Antalffy of Please SVB line question the XX:XX Leerink.

Danielle Antalffy

so haven't Good afternoon, a much Thanks a and taking X you had I I question. Hi. two-part XX:XX the approval, to chance for Omnipod have everyone. on exciting. question congratulate very

second competitive still are looking release. the why of more come is just the learnings the AID if U.S., for have it how, greater that internationally, learn. and patients first question so appreciate And curious it the feels patient you an I is best patients you to strong very selection. and a on growth limited could bit still market about I'm it exactly Thank the is much part limited about in feedback, AID's then just release guys little But color pressure a from that love little how the you had you're So the the the more versus I competitive. sort bit about clinicians, is to Is what with like U.S., XX:XX train We more internationally of internationally. market looking talk more mean much.

Shacey Petrovic

and Danielle. international Yeah. a then with limited start dynamics insight And can Brett market maybe some the release into give XX:XX market Thanks, I'll question AID. around

don't market For to users the release, we're looking our remember lock said, into four-year limited agreements. Brett understand really we what as

that means who X. so that has access And coverage access has Omnipod and market and everybody to

be than could United the thousands, XXX,XXX more in that's of users States. XXs not if So

training are be if be so to there them and on a prescription patient segments. Omnipod are even we onto pathways. XX:XX to but get training are we to through virtual and need not to to our to want able product, for certainly these product, able you today onto you be self-serve, So or a should to a that meet different you to with them DexCom, so want pathways able the And purely physician get clinician go need

patient with of then does that involve for example a clinician, everybody focused as possible off to incredibly there MDI want be on meeting this to with pathway, example really and pathways, physician's experience an success the have a to and that that's user is product itself of the good the most that user So of as make very designed the simple, office and is use opposed test satisfied a are the patient. something that physician the for to different to the training training. simple as be for we been product it's a other will and hands having And the good pathway after myriad sure is

building Brett your just And second to of patient across are the XX:XX the feedback that we need those and then types we are of of looking take then access experience pathways. amount each testing things confidence the pathways, And across of test. good to things that we have we're types to we're of a of make of course, those we those are ask the and the I'll question. part and background. those sure patients then good But in each So that in get

Bret Christensen

XX:XX Yeah. Hi, Danielle. Bret. Its

in AID years than U.S. now. in couple but appear it's the competition about that I was One, six a it AID internationally had For know U.S., for stronger the competition of things. does we've it

you'd exist is been to lift. living U.S. things, doesn't of XX% just so, are coming if lower see remember The us, of is we've one significantly if three take with the the Type and really Type and to from of that number tailwinds out helped you So that one. exist markets those our new U.S. new that our it's in pharmacy starts, XX% the with something all internationally. just same it been the starts to were second X, are XX:XX extent with And really international in that's don't X results there have

we available significant third It's not few really the been get in it's years, of our the the So really experience as premium DTC it Pods revenues all for U.S. markets is to the us in our of the pharmacy spend. And pharmacy the channel, last a been both as pricing well of U.S. the outside that's really over helps significant

something So just markets everywhere. the that And working that yeah, that extent we that's is not to tried just pharmacy in models Germany, do international then, Canada, something today. we've -- the that is although really markets, in we the the can have we're benefit, the on but something something like in our it's it's not pay-as-you-go U.S. it

in our markets. international new So AID is

X better list internationally. compete So now change it's launch and tailwinds, between on today that we're we and something a when got Omnipod just that feeling those we work we and to to so that have

Operator

UBS. of question Thank I comes from Matt the Taylor Please line from ahead. next XX:XX our show you. go

Matt Taylor

question. development. XX:XX there for you iOS the talk that. Thank and development, I the remarks next you're timing give on prepared had for an the Could update in you taking us and you just you color Apple that about that making said saw progress on that any can give steps

Shacey Petrovic

Matt. Sure, no for iOS excited for work timeline Yeah. we are and Thanks you had it. a but certainly is We the going the is work and we well XX:XX can I there, that question. have tell while the there about underway update do --

iOS. launch to control and Android into for factor on submission, learnings those take plan always with the market release phone the limited been Our plan from our and has the our

the before right want up submitting, do be submission. require a pole does in we XXX(K) not would work. but so to And the This it's wait through likely now, the tent, to get end that's completion to the technical long we that, of

control we work to and with full up learnings our are XXX(K) then the for then Android release So that going from to factor and limited submit market technical phone in clearance wrap FDA. any our

Operator

show from Steve of ahead. Lichtman comes the question I Oppenheimer. Please you. go next from Thank line XX:XX our

Steve Lichtman

you. Thank everyone. Hi, XX:XX

people past should talked impact we the think for about the think, positively Shacey, I Omnipod new to about flow you, you're the how does before are given wondering provide explicitly not if that on available, no capital it building an upfront who Just in potential to into X even you've even for patient X Omnipod can switch opportunity guidance. that XXXX launch, full once

Shacey Petrovic

And it I not on insurer guess covers new Yeah. the is once product avoid illustration we and X think to the would to closer X. Thanks they QX launch I that the back we product closer to get question, the helping for to XX:XX is fact to educate trying of innovation main bring Omnipod as on and we to the get is and choice right. focus fact illustrative the are think point a get example that as we model, and as be they'll don't a there ensure there I customers launches Omnipod people the that delaying business that step product. see get people they're their slowdown their market the new of of convert a and I get QX before to Steve. an or and What able I innovation can an to think just over clinicians

to a model bring power at we and exciting. think for So down the a don't as that's wouldn't Insulet. look slow necessarily indication and patients great it's as but innovation I of it's of market I It's very it thing the great that great upside, a for we business an new thing

Bret Christensen

for of on XX:XX to anybody because on that's both to patients component is there Bret. training is this pathways and Yeah. self-service health the is our DASH. be today DASH message quickest Steve, X Part that, is Omnipod care providers

X. full to X through they when fashion a Omnipod become a for away. release wants training the best doesn't go that Omnipod So that right today DASH quickly on is The to onboard on more anybody they're bottleneck able really start in out X market training, Omnipod thing start training the that can't do comes and on so with self-serve

which that's trying what [indiscernible] people driving really from but we're do. not it is resonating. new message starts, preventing So additional is Shacey it's the waiting, agree that's to

Wayde McMillan

end to just part And the months’ us If of six us build to the about I XX:XX way model with of three we're push more into guidance or of could we months that release at that end the lower to of we build on if push the can the we into help end starts up helps the the higher then, the our think six is, guide. then limited obviously of period that X it XXXX. The annuity shorter to up in year us Steve, momentum Yeah. it And that's market nine timeframe, the pick how depending that on one Omnipod question. to year could then, the throughout end reasons at are and of the successful to end as guide.

Operator

go O'Brien XX:XX Thank you. next question the Please I line ahead. of Piper show Matthew our comes from from Sandler.

Matthew O'Brien

taking for XX:XX Thanks question. Good Afternoon. the

gets kind patients to we I be of Steve just the with patients to August, dovetails you new six to full be that away about for going mean not say to it's going going market patients Omnipod So able September. us off what they're kind able bore asking really so OX in probably go get more was really Are OX? X to new a months after to figuring spending release conversion to after lot limited how to factor. Thanks. early of kind of of right reps time are the And to until or so existing convert selling XXXX. you

Bret Christensen

Hi. XX:XX Yeah, Matt. I is can Bret. one. take that This

are compensated and new on Our sales starts. Omnipod new starts to reps

starting process to the conversion starts. is allow do focus our pump that that solely we to and to Omnipod. process Those should intent. talked new on the on-boarding tools them that our ordering That building coming So on they're about a or going are that and are to brand from focus really MDI users base tube want customer from new to new both

reasons this always these and Omnipod upgrade can fee building we be and to for version we spending will in that of self-service innovate patients technology, As a latest will why think self-serve been so people this always now latest able no one model, upgrade thing. able about to we've pay-as-you-go the good X, cycles that's of the it's of years launch to upfront and the short anticipation Omnipod. be to in the tools And Omnipod

is the this We're a of LMR And on put intent, we've X people the because reasons systems over we're so confident that why the one These to to Omnipod and test had Omnipod starts on system, their develop own. and it. intent, partners this fantastic to our X the pretty migrate sales for remember focus product is our is new we've range to want love people that those ordering we on marketing product got year. we teams and because in it so new on want existing our onboarding that that a LMR we've is and really testing quickly

Operator

XX:XX queue our Thank ahead. Canaccord. in comes Kyle from the you. from showing go Please question I'm last Rose

Kyle Rose

me Good evening, for thanks fitting Great. XX:XX in. and everyone,

I work of if manufacturing. little just a guess ask us Wayde, think for I bit, future of picture more bigger I you're just a business in And the to doing to So you XXX reiterated about trying model unpack think about you could I being comment a I when ballpark I'm of on the understand the wanted question. that leverage just guess years bps.

what but some assuming investments maybe to the the of scalable about an forward take or is upfront, in infrastructure be I I DTC place more guess think be bps need perspective, that things advertising. thinking, led that fixed XXX appear making. I topline onboarding, year-over-year they to the moving from cost would pharmacy that constrain the you're like of a patient growth they long-term investments understand to put there. do channel, additional investments kind only

Wayde McMillan

we're capitalize a position market and afternoon, level key it, our Yeah. a very is on to summary want through so position we X X the continue The thesis. do here both in in to and a this financial Type to ourselves to position that going the is Kyle. see invest available leadership XX:XX areas. to total a to position Good very Type major within able And that and that leadership and so large we in leadership be differentiated

significant driving years of one the for one in but innovation investments being to come. of R&D ones Our the mentioned, largest you didn't

advancements have As a Shacey our TAM of pipeline also now about talked behind that, that prepared for for that generations we've we being in course, But products our expansion, projects said significant our publicly clinical further of for lot invested current submission in is of remarks, timelines. the have expansion. in international

the pipeline. So just coming lot in a

So stays make continue you sure investment -- And I in R&D want for as in this penetrating manufacturing, in to obviously. available continue market capacity this heavy us. large XX:XX to then to ahead mentioned

You mentioned leveraging the pharmacy channel.

and and lift we awareness are so it so for We've more almost benefits big that, injections, Brett both all right, Type got in But the drive continuing drive using me one pharmacy in volume flowing X that to force those the going also area market channel getting DTC do almost Shacey the to X that. product the And and in regions. we're to XX:XX then and we've of our who around developing the half in efficient needed invest is us. capabilities significant through we're earlier, over daily are our our a investments also on major to X investment, but the as the pretty areas in pardon job investment as the of is other Type is the Type X multiple got of pretty we're -- deliver Type and space. to direct-to-consumer, all mentioned we and which for of for Type and now heavy as the You're initiatives a more as of earlier expansion making -- all side, from sales majority government affairs, market that well market do people still X is the international and the highlighted is for regulatory see those to

and to where going ourselves financially stronger going year each on cycle, in this much we're year year-to-year. that, had EBITDA to basis to strengthen we're but heavy see operating we get we mentioned, investment to continue and want from this that We improvement we're that our build to to now also XXX you we a place profile. to nice we're step targeting continue step-up And continuing ourselves intentionally And as did points to in profile. so and and a margins way financial our stronger financial of

that's plan to take of over time, differentiated So the leadership our advantage in for us continuing here. position

for also profile While the company. financial stronger a building

Operator

further to at time. Thank the no questions for like to conference would I back XX:XX showing I'm closing. you turn sir, Shacey this now Petrovic

Shacey Petrovic

come son thinking users changed wonderful a a with you, Bethany, moment be Thank Omnipod Omnipod lives. of in with to allowed the a He weeks today during of more through a is for sugar received has morning third quote personal my bottled XX-year-old me I of not my has been taken just Kevin, true. and on managing take a some X row to on few X has XX:XX father been mother quote, me from up who X laided shared the limited a finally mentally a over toll diabetes decades I X its no present slept In my of long two stay X has the uninterrupted make frustration Omnipod night John, perfect and work for for to those words, am lows. challenges his hard pump first diabetes. to diabetes; has my try for dream overnight I'm and I've up And son, time dream lifetime his constantly want has is share feedback the this in me because one-year-old tired. about quote wife, how love time. and a Dalam. my a blood strong all to about your we've their I own and shared for kids reality. and very Omnipod Thank you unsolicited With woke Omnipod shared a of market who what release. a a

unmatched So community. we to to and broader cannot wait bring diabetes the Omnipod benefits X its

like great So millions John Kevin of their families. a and just and that have us it and can help again it's for for evening. joining Bethany, people today Thanks more doing

Operator

XX:XX you a conference. day. gentlemen, and for wonderful Thank participation concludes and today's Ladies this have

disconnect. all may You

Insulet (PODD) 24 Feb 222021 Q4 Earnings call transcript